Thursday, October 05, 2017 9:31:55 PM
Ok so before you post any article you might want to do a little bit more DD. Try contacting the company see what has progressed.
Lets start with this, 5 phase 3 trials. Well each one has about 33% chance of being FDA approved. So that means at least one or even two make it.
1) Do they have the cash to get there? Well yes they do!
2) Do they have good management with FDA experience? Yes they do!
3) Do they have a broad pipeline meeting all time frames so far? Yes they do.
4) Is it possible to do a placebo trial on patients unaware they are even receiving treatment? Well thats pretty pointless. (FXS)
5) Do you know how much the phase 3 trials for FXS cost? Ok ill tell you about 5-10 million total. Best and cheapest runway for success!
6) How about there are no known treatments for spectrum disorders.
7) How about patented past 2030 with orphan drug designation giving almost a decade of exclusive marketing!
Ok now lets talk about O/A or osteoarthritis.
Met the most important secondary endpoints! Worked in men and not women. Restructure this with the FDA for phase 3 probably gonna have a solid update for this in December.
O/A largest market but also costly phase3 ($20+ million 300+ patients)
How about Zyn001? Well the only pro THC derived transdermal synthetic thats patent protected with all the same as above minus the results.
I tell you what my bet is here! any placebo test is an open and shut case
i believe that passing on this opportunity to buy the stock will be a large mistake people will look back and say wow i could have bought that for how much?! Its already traded at $25 before any results, has a low float enough cash till 2019 and is in the largest market space with the highest potential growth in the next 5 years!
Sorry for the rant here but i have alot to say and this article was pitiful! Longs will be winners here mark my words!
Thanks for the support of all my friends who held on through this rough ride, we should be rewarded handsomely!
-HT
Recent ZYNE News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 12:22:51 AM
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 10/19/2023 08:48:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/12/2023 04:15:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:12:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/11/2023 02:02:08 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 10/11/2023 01:27:41 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 10/11/2023 01:27:00 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 10/11/2023 12:56:22 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 10/11/2023 12:31:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 12:17:36 PM
- HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE • PR Newswire (US) • 10/11/2023 12:00:00 PM
- Form SC 14D9/A - Solicitation, recommendation statements: [Amend] • Edgar (US Regulatory) • 10/04/2023 09:29:21 PM
- Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions • GlobeNewswire Inc. • 10/04/2023 08:05:00 PM
- Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 • GlobeNewswire Inc. • 09/29/2023 01:00:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM